Drug Transporter (DT) Information

General Information of DT
DT ID DTD0247
Gene Name SLC29A1
Protein Name Equilibrative nucleoside transporter 1
Gene ID
2030
UniProt ID
Q99808
TCDB ID
2.A.57.1.1
3D Structure

Modelled DT Structure

Method: loop building

Template PDB: 6OB6_A

Identity: 92.308%

Minimized Score: -1219.009 kcal/mol

Detail: Structure Info

Synonyms ENT1; Equilibrative NBMPR-sensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; Nucleoside transporter, es-type; SLC29A1; Solute carrier family 29 member 1
DT Family Equilibrative Nucleoside Transporter (ENT) Family ;
Tissue Specificity Detected in erythrocytes (at protein level).Expressed in heart, brain, mammary gland, erythrocytes andplacenta, and also in fetal liver and spleen.
Function This transporter mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs).
Disease(s) Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1]
Colon cancer [ICD-11: 2B90.Z]
Herpes simplex virus infection [ICD-11: 1F00]
Anxiety [ICD-11: MB24.3]
Endogenous Substrate(s) Nucleosides
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(α) Mutation-induced Structural Variation
Mutation-induced Structural Variation (MSV)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            8 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Adenosine
 Approved Drug Info Anxiety MB24.3 [1]
Clofarabine
 Approved Drug Info Juvenile myelomonocytic leukemia 2A42 [2]
Cytarabine
 Approved Drug Info Acute myeloid leukemia 2A60 [3]
Entecavir
 Approved Drug Info Chronic hepatitis B infection 1E51.0 [4]
Fluorouracil
 Approved Drug Info Stomach cancer 2B72 [5]
Mercaptopurine
 Approved Drug Info Acute lymphoblastic leukemia 2B33.0 [6]
Ribavirin
 Approved Drug Info Hepatitis C virus infection 1E50.2, 1E51.1 [7]
Trifluridine
 Approved Drug Info Herpes simplex virus infection 1F00 [8]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Tecadenoson
 Discontinued in Phase 3 Drug Info Paroxysmal supraventricular tachycardia BC81.Z [9]

Drug-DT Affinity Assessed by Cell Line

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Tecadenoson Discontinued in Phase 3 Drug Info CCRF-CEM cells-ENT1 Km = 24 microM [9]
Tecadenoson Discontinued in Phase 3 Drug Info Oocytes-ENT1 Km = 196 microM [9]
References
1 Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol. 2006 Aug;208(2):451-60.
2 Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
3 FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
4 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
5 Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2241-9.
6 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
7 Effects of dipyridamole coadministration on the pharmacokinetics of ribavirin in healthy volunteers. Drug Metab Pharmacokinet. 2013;28(5):406-10.
8 Lonsurf, INN-trifluridine/tipiracil.
9 Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1. Drug Metab Dispos. 2013 Apr;41(4):916-22.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.